RESTICTED DRUGS Risk Evaluation and Mitigation Strategies--REMS

Slides:

Advertisements

Similar presentations

The U.S. Approach to Risk Management Daniel Kracov Track II: Pharmacovigilance and Drug Safety Risk Management: - EU and US Developments International.

Advertisements

Common/shared responsibilities between jobs.

The Pharmaceutical Agent Order. Prescription An oral or written record of a physicians order to pharmacist to dispense medication to patient.

1 Goals of a Lotronex ® Risk Management Program Toni Piazza-Hepp, Pharm.D. Deputy Director Division of Surveillance, Research and Communication Support.

National Adult Clozapine Titration Chart

iPLEDGE The new isotretinoin registry iPledge timelines September: initial mailing to all prescribers October: Registration by pre-populated form Mid-October:

Consumer Safety and Drug Regulations

Disease State Management The Pharmacist’s Role

 To analyse the counselling, prescribing and monitoring practices of Isotretinoin by doctors in my practice.  Are we adhering to guidelines?  Where.

Medication Guides Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications.

The Value of Medication Therapy Management Services

REMS Update NORD Corporate Council Meeting May 14, 2013

Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used.

Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.

Dr Nigel Hawkins - UWS.  Prescription opiate abuse is something that all GP’s are familiar with and so all GPs need to know how to manage it  This talk.

Personal and Consumer Health 1. Objectives 1.Demonstrate the ability to access and describe health information, health products, and health services in.

1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.

Clinical Pharmacy Basma Y. Kentab MSc..

April 8, 2005FDLI Annual Conference 1 Labeling Prescription Drugs for Physicians and Consumers (FDA Perspective) Paul J. Seligman, MD, MPH Director, Office.

Standard 4: Medication Safety Advice Centre Network Meeting Margaret Duguid Pharmaceutical Advisor February 2013.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

Pharmacy and Therapeutics Committee

FDA REMS Program REMS: Risk Evaluation & Management Strategy

Chapter 1. OBJECTIVES  see p-2 of text book KEY TERMS / CONCEPTS  controlled substances  Drug Enforcement Administration (DEA)  drug standards  Food.

Chapter 3: Community and Ambulatory Care Pharmacy Practice.

Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.

Responsibilities and Principles of Drug Administration

Extending nursing roles through protocols and standing orders workshop Gpnz/rnzcgp conference Auckland 4/9/2011 D –

In Which Areas Have Clinical Pharmacists Been the Most Successful in Patient Care ? Hospital inpatient unit (wards) –Therapeutic drug monitoring –Anticoagulation.

The Value of Medication Therapy Management Services.

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Evolution of Risk Management for Systemic Retinoids Evolution of Risk Management for.

For Pain or Not for Pain: Methadone Madness

Standard 4: Medication Safety Advice Centre Network Meeting Margaret Duguid Pharmaceutical Advisor February 2013.

FDA Risk Management Workshop: Concept Paper: Risk Management Programs April 10, 2003 Gary C. Stein, Ph.D. Director of Federal Regulatory Affairs American.

Integrate Risk Evaluation & Mitigation Strategies (REMS) with Health Management Craig Kephart, President & CEO Centric Health Resources, Inc. July 15,

CHAPTER 1 The Nursing Process and Drug Therapy Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.

ACCESS TO MEDICINES - POLICY AND ISSUES

Methods to Evaluate and Improve National Policy: Focus on 2011 WHO Guidelines and PPSG Global Policy Evaluation Aaron M. Gilson, MS, MSSW, PhD Research.

Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao

Using Medicines Safely (2:50) Click here to launch video Click here to download print activity.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 IsotretinoinIsotretinoin Background.

Coagulants By: Autum White. Sources   

Focus Area 17: Medical Product Safety Progress Review November 5, 2003.

“USAPI-PHARMACY ASSOCIATION - RESPONSE TO NCD ROADMAP” Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa 51 st 1-18 nov 2011 Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa.

Preventing Errors in Medicine

Who are Health-System Pharmacists? Pharmacists are healthcare professionals with extensive education and training in the pharmaceutical sciences. Education.

July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.

Accutane FDA (Section Name - Saver’s Initials) 3/9/00 12:50 PM 1 Risk Management Options Russell Ellison, MD Chief Medical Officer Vice President, Medical.

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

The Pharmaceutical Agent Order. Prescription An oral or written record of a physician ’ s order to pharmacist to dispense medication to patient. who can.

Daniel Wermeling, Pharm.D. Professor, College of Pharmacy.

MTM Medication Therapy Management. What is Medication Therapy Management? From 1996 to 2006, the number of prescription medications dispensed increased.

 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.

Developing, Pilot Testing & Evaluating RiskMAP Interventions Annette Stemhagen, DrPH, FISPE Vice President UBC Epidemiology & Risk Management The FDA Regulatory.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.

Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong

Introduction to Pharmacy Practice

Comments to the FDA on Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription Marissa Schlaifer, RPh Director of Pharmacy.

Introduction to Clinical Pharmacy

Comments to the FDA on Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription Marissa Schlaifer, RPh Director of Pharmacy.

Black Box Warning What You Need To Know.

Reviewed By- Dr Vijay Agarwal Dr Chander Mohan Bhagat Dr Lallu Joseph

Began with the passage of the 1906 Pure Food and Drugs Act

Pharmacy practice experience I

Pharmacy practice and the healthcare system Ola Ali Nassr

Essentials of Good Pain Care: A Team-Based Approach

Compounded Drugs and Lack of Premarket FDA-Approval

Hospital pharmacy.

Presentation transcript:

RESTICTED DRUGS Risk Evaluation and Mitigation Strategies--REMS With each drug/biologic safety issue posing a serious risk, the question for FDA will be: to REM or not to REM? REMS---Food and Drug Administration Amendments Act of 2007 in 2006 the FDA listed 156 REMS for prescription medicines (128) and biologics (28) intended to ensure the benefits of the medication outweigh its risk why REMS??--Public outcry over revelations of unforeseen risks from trusted medicines(rofecoxib, valdecoxib, and salmeterol

RESTICTED DRUGS Components of REMS FDA can require a manufacturer to implement a REMS Components of REMS 1--Medication Guides--required for drugs and biologics when the FDA determines that: (a) certain information is necessary to prevent serious adverse effects, (b) patient decision-making should be informed by information about a known serious side effect of a product, or (c) patient adherence to directions for the use of a product is essential to its effectiveness.

RESTICTED DRUGS 2--Communication Plans-- Letters to healthcare providers; Disseminating information about the REMS to encourage implementation; and Disseminating information through professional societies about any serious risks of the drug and any protocol to assure safe use.

RESTICTED DRUGS 3--Elements to Assure Safe Use(ETASU) may include one or more of the following Special training, certifications, or demonstration of experience for prescribers of the drug/biologic Certification of pharmacies, practitioners, or healthcare settings that dispense the drug/biologic Limitations as to the healthcare settings where the drug/biologic may be dispensed Evidence of special safe-use conditions--patients receive the drug/biologic only after specified authorization,proof of counseling, periodic blood tests monitor the number of prescriptions dispensed, adverse events,

Examples of Drugs with REMS alosetron (Lotronex) clozapine (Clozaril, Fazaclo) isotretinoin (Accutane, Amnesteem, Claravis, Sotret) thalidomide (Thalomid) dofetilide (Tikosyn)

Alosetron Treats a type of irritable bowel syndrome (IBS) Serious adverse reactions of gastrointestinal tract some necessitate a blood transfusion or surgery some even lead to death Restricted by Prescription Program for Lotronex (PPL) requires physician enrollment & submission of Patient-Physician Agreement Form Prescriptions must be written by physician & must include PPL sticker on face of prescription

Clozapine Treats patients with schizophrenia Can cause serious drop in white blood cells monitoring must be done regularly Pharmacies must register to dispense clozapine Specific day supply may be dispensed (1, 2, or 3 weeks depending on monitoring frequency) Pharmacy must receive documentation of blood work

Isotretinoin Treats severe acne & can cause serious birth defects iPledge Program for isotretinion registration required by doctors patients Pharmacies must meet specific requirements / answer questions with iPledge Program each time drug dispensed quantity dispensed is limited prescription must be picked up within limited time

Thalidomide Treats multiple myeloma/erythema nodosum leprosum Causes birth defects Thalidomide Education & Prescribing Safety (S.T.E.P.S.) Program prescribers, patients, pharmacies must register pharmacy must verify that the prescriber is registered with S.T.E.P.S. before dispensing medication

Dofetilide Treats irregular heart rhythms Can cause serious complications Patients must be hospitalized to initiate therapy Tikosyn in Pharmacy System (T.I.P.S.) prescribers & pharmacists must register pharmacy must verify the prescriber’s registration

special rx programs methadone maintenance tx----MMT methadone/dolpohine/methadose is used for opiod addiction. do don’t give over 1 day supply. must ingest at dr office or drug tx center. also for chronic pain or cancer pain. suboxone and subutex sch2 sublingual must have pt do paperwork. you may get rx for this but requires special training for dr to rx. will have X with DEA number.